

16 Oct 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: Merck and Moderna's cancer vaccine deal; six pivotal trial readouts to look out for in Q4; Pfizer leads big pharma M&A so far this year; making the metaverse work in pharma; and a first approval for a Chinese mRNA vaccine.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 14 October 2022, including: [Merck & Co., Inc.](#) and [Moderna, Inc.](#)'s cancer vaccine deal; six pivotal trial readouts to look out for in Q4; [Pfizer Inc.](#) leads big pharma M&A so far this year; making the metaverse work in pharma; and a first approval for a Chinese mRNA vaccine.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Merck & Co. Pounces On Moderna mRNA-Based Cancer Vaccine Option](#)" - Scrip, 12 Oct, 2022.)

(Also see "[Six Pivotal Trial Readouts To Look Out For In Q4](#)" - Scrip, 11 Oct, 2022.)

(Also see "[Pfizer Leads Big Pharma M&A In 2022 – But Is There More To Come?](#)" - Scrip, 12 Oct, 2022.)

(Also see "[Doing It The Nike Way – Novartis, AstraZeneca On Making The Metaverse Work](#)" - Scrip,

12 Oct, 2022.)

(Also see "[\*Can First Approval Of China mRNA Vaccine Change 'COVID Zero' Approach?\*](#)" - Scrip, 11 Oct, 2022.)

[\*Click here to explore this interactive content online\*](#) ✨